{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:15:15Z","timestamp":1772572515806,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00262-020-02577-w","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T15:04:07Z","timestamp":1587567847000},"page":"913-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-8459","authenticated-orcid":false,"given":"Maria Christina","family":"Cox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2771-6813","authenticated-orcid":false,"given":"Caterina","family":"Lapenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-5589","authenticated-orcid":false,"given":"Stefano M.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"2577_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman A (2018) Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol 93:296\u2013305. https:\/\/doi.org\/10.1002\/ajh.24937","journal-title":"Am J Hematol"},{"key":"2577_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P et al (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15:424\u2013435. https:\/\/doi.org\/10.1016\/S1470-2045(14)70027-0","journal-title":"Lancet Oncol"},{"key":"2577_CR3","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the prima study. J Clin Oncol 37:2815\u20132824. https:\/\/doi.org\/10.1200\/JCO.19.01073","journal-title":"J Clin Oncol"},{"key":"2577_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"key":"2577_CR5","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","volume":"28","author":"C Casulo","year":"2017","unstructured":"Casulo C, Nastoupil L, Fowler NH et al (2017) Unmet needs in the first-line treatment of follicular lymphoma. Ann Oncol Off J Eur Soc Med Oncol 28:2094\u20132106. https:\/\/doi.org\/10.1093\/annonc\/mdx189","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2577_CR6","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA et al (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the gallium study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36:2395\u20132404. https:\/\/doi.org\/10.1200\/JCO.2017.76.8960","journal-title":"J Clin Oncol"},{"key":"2577_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA et al (2019) Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134:761\u2013764. https:\/\/doi.org\/10.1182\/blood.2019000258","journal-title":"Blood"},{"key":"2577_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw255","author":"K Maddocks","year":"2017","unstructured":"Maddocks K, Barr PM, Cheson BD et al (2017) Recommendations for clinical trial development in follicular lymphoma. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djw255","journal-title":"J Natl Cancer Inst"},{"key":"2577_CR9","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379:934\u2013947. https:\/\/doi.org\/10.1056\/NEJMoa1805104","journal-title":"N Engl J Med"},{"key":"2577_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.15797","volume":"185","author":"H Chiu","year":"2019","unstructured":"Chiu H, Trisal P, Bjorklund C et al (2019) Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. Br J Haematol 185:240\u2013253. https:\/\/doi.org\/10.1111\/bjh.15797","journal-title":"Br J Haematol"},{"key":"2577_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-3083.2009.02340.x","volume":"70","author":"B Bogen","year":"2009","unstructured":"Bogen B, Ruffini P (2009) Review: to what extent are T cells tolerant to immunoglobulin variable regions? Scand J Immunol 70:526\u2013530. https:\/\/doi.org\/10.1111\/j.1365-3083.2009.02340.x","journal-title":"Scand J Immunol"},{"key":"2577_CR12","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","volume":"29","author":"SJ Schuster","year":"2011","unstructured":"Schuster SJ, Neelapu SS, Gause BL et al (2011) Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29:2787\u20132794. https:\/\/doi.org\/10.1200\/JCO.2010.33.3005","journal-title":"J Clin Oncol"},{"key":"2577_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","volume":"32","author":"R Levy","year":"2014","unstructured":"Levy R, Ganjoo KN, Leonard JP et al (2014) Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol 32:1797\u20131803. https:\/\/doi.org\/10.1200\/JCO.2012.43.9273","journal-title":"J Clin Oncol"},{"key":"2577_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0210-z","author":"SK Wculek","year":"2019","unstructured":"Wculek SK, Cueto FJ, Mujal AM et al (2019) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-019-0210-z","journal-title":"Nat Rev Immunol"},{"key":"2577_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","volume":"5","author":"F Wimmers","year":"2014","unstructured":"Wimmers F, Schreibelt G, Sk\u00f6ld AE et al (2014) Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 5:165. https:\/\/doi.org\/10.3389\/fimmu.2014.00165","journal-title":"Front Immunol"},{"key":"2577_CR16","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1084\/jem.191.10.1777","volume":"191","author":"SM Santini","year":"2000","unstructured":"Santini SM, Lapenta C, Logozzi M et al (2000) Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777\u20131788. https:\/\/doi.org\/10.1084\/jem.191.10.1777","journal-title":"J Exp Med"},{"key":"2577_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-71029-5_14","author":"SM Santini","year":"2009","unstructured":"Santini SM, Lapenta C, Santodonato L et al (2009) IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/978-3-540-71029-5_14","journal-title":"Handb Exp Pharmacol"},{"key":"2577_CR18","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/blood.v98.10.3022","volume":"98","author":"S Parlato","year":"2001","unstructured":"Parlato S, Santini SM, Lapenta C et al (2001) Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98:3022\u20133029. https:\/\/doi.org\/10.1182\/blood.v98.10.3022","journal-title":"Blood"},{"key":"2577_CR19","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1158\/1078-0432.CCR-19-0709","volume":"25","author":"MC Cox","year":"2019","unstructured":"Cox MC, Castiello L, Mattei M et al (2019) Clinical and antitumor immune responses in relapsed\/refractory follicular lymphoma patients after intranodal injections of IFN\u03b1-dendritic cells and rituximab: a phase I clinical trial. Clin Cancer Res 25:5231\u20135241. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0709","journal-title":"Clin Cancer Res"},{"key":"2577_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1479-5876-3-24","volume":"3","author":"DF Stroncek","year":"2005","unstructured":"Stroncek DF, Basil C, Nagorsen D et al (2005) Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J Transl Med 3:24. https:\/\/doi.org\/10.1186\/1479-5876-3-24","journal-title":"J Transl Med"},{"key":"2577_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1479-5876-5-46","volume":"5","author":"M Korthals","year":"2007","unstructured":"Korthals M, Safaian N, Kronenwett R et al (2007) Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med 5:46. https:\/\/doi.org\/10.1186\/1479-5876-5-46","journal-title":"J Transl Med"},{"key":"2577_CR22","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/eji.200535579","volume":"36","author":"C Lapenta","year":"2006","unstructured":"Lapenta C, Santini SM, Spada M et al (2006) IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 36:2046\u20132060. https:\/\/doi.org\/10.1002\/eji.200535579","journal-title":"Eur J Immunol"},{"key":"2577_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2011-06-363564","volume":"119","author":"F Spadaro","year":"2012","unstructured":"Spadaro F, Lapenta C, Donati S et al (2012) IFN-\u03b1 enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 119:1407\u20131417. https:\/\/doi.org\/10.1182\/blood-2011-06-363564","journal-title":"Blood"},{"key":"2577_CR24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.imbio.2010.10.003","volume":"216","author":"L Lattanzi","year":"2011","unstructured":"Lattanzi L, Rozera C, Marescotti D et al (2011) IFN-\u03b1 boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology 216:537\u2013547. https:\/\/doi.org\/10.1016\/j.imbio.2010.10.003","journal-title":"Immunobiology"},{"key":"2577_CR25","doi-asserted-by":"publisher","first-page":"e17364","DOI":"10.1371\/journal.pone.0017364","volume":"6","author":"SM Santini","year":"2011","unstructured":"Santini SM, Lapenta C, Donati S et al (2011) Interferon-\u03b1-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12. PLoS ONE 6:e17364. https:\/\/doi.org\/10.1371\/journal.pone.0017364","journal-title":"PLoS ONE"},{"key":"2577_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4049\/jimmunol.1600262","volume":"197","author":"C Lapenta","year":"2016","unstructured":"Lapenta C, Donati S, Spadaro F et al (2016) NK cell activation in the antitumor response induced by IFN-\u03b1 dendritic cells loaded with apoptotic cells from follicular lymphoma patients. J Immunol 197:795\u2013806. https:\/\/doi.org\/10.4049\/jimmunol.1600262","journal-title":"J Immunol"},{"key":"2577_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2018.03.025","volume":"113","author":"J Bandola-Simon","year":"2019","unstructured":"Bandola-Simon J, Roche PA (2019) Dysfunction of antigen processing and presentation by dendritic cells in cancer. Mol Immunol 113:31\u201337. https:\/\/doi.org\/10.1016\/j.molimm.2018.03.025","journal-title":"Mol Immunol"},{"key":"2577_CR28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.V99.5.1517","volume":"99","author":"JM Timmerman","year":"2002","unstructured":"Timmerman JM, Czerwinski DK, Davis TA et al (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517\u20131526. https:\/\/doi.org\/10.1182\/blood.V99.5.1517","journal-title":"Blood"},{"key":"2577_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2008-06-165654","volume":"113","author":"M Di Nicola","year":"2009","unstructured":"Di Nicola M, Zappasodi R, Carlo-Stella C et al (2009) Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 113:18\u201327. https:\/\/doi.org\/10.1182\/blood-2008-06-165654","journal-title":"Blood"},{"key":"2577_CR30","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1182\/blood-2011-06-364570","volume":"118","author":"R Zappasodi","year":"2011","unstructured":"Zappasodi R, Bongarzone I, Ghedini GC et al (2011) Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood 118:4421\u20134430. https:\/\/doi.org\/10.1182\/blood-2011-06-364570","journal-title":"Blood"},{"key":"2577_CR31","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1158\/0008-5472.CAN-10-1825","volume":"70","author":"R Zappasodi","year":"2010","unstructured":"Zappasodi R, Pupa SM, Ghedini GC et al (2010) Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70:9062\u20139072. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1825","journal-title":"Cancer Res"},{"key":"2577_CR32","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","volume":"15","author":"N Selenko","year":"2001","unstructured":"Selenko N, Majdic O, Draxler S et al (2001) CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 15:1619\u20131626. https:\/\/doi.org\/10.1038\/sj.leu.2402226","journal-title":"Leukemia"},{"key":"2577_CR33","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2007-03-080507","volume":"111","author":"SN Franki","year":"2008","unstructured":"Franki SN, Steward KK, Betting DJ et al (2008) Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 111:1504\u20131511. https:\/\/doi.org\/10.1182\/blood-2007-03-080507","journal-title":"Blood"},{"key":"2577_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2014-07-592162","volume":"125","author":"A Kolstad","year":"2015","unstructured":"Kolstad A, Kumari S, Walczak M et al (2015) Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood 125:82\u201389. https:\/\/doi.org\/10.1182\/blood-2014-07-592162","journal-title":"Blood"},{"key":"2577_CR35","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"L Hammerich","year":"2019","unstructured":"Hammerich L, Marron TU, Upadhyay R et al (2019) Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med 25:814\u2013824. https:\/\/doi.org\/10.1038\/s41591-019-0410-x","journal-title":"Nat Med"},{"key":"2577_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2006.08.008","volume":"25","author":"J Vilcek","year":"2006","unstructured":"Vilcek J (2006) Fifty years of interferon research: aiming at a moving target. Immunity 25:343\u2013348. https:\/\/doi.org\/10.1016\/j.immuni.2006.08.008","journal-title":"Immunity"},{"key":"2577_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.hoc.2004.03.002","volume":"18","author":"F Guilhot","year":"2004","unstructured":"Guilhot F, Roy L, Guilhot J, Millot F (2004) Interferon therapy in chronic myelogenous leukemia. Hematol Oncol Clin North Am 18:585\u2013603. https:\/\/doi.org\/10.1016\/j.hoc.2004.03.002","journal-title":"Hematol Oncol Clin North Am"},{"key":"2577_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/030089169508100407","volume":"81","author":"M Morroni","year":"1995","unstructured":"Morroni M, Cinti S (1995) Hairy cell leukemia: an ultrastructural study of hairy cells before and after interferon therapy. Tumori 81:249\u201355","journal-title":"Tumori"},{"key":"2577_CR39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO.1999.17.4.1254","volume":"17","author":"PL Zinzani","year":"1999","unstructured":"Zinzani PL, Magagnoli M, Galieni P et al (1999) Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 17:1254. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1254","journal-title":"J Clin Oncol"},{"key":"2577_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ophtha.2011.09.008","volume":"119","author":"MA Blasi","year":"2012","unstructured":"Blasi MA, Tiberti AC, Valente P et al (2012) Intralesional interferon-\u03b1 for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results. Ophthalmology 119:494\u2013500. https:\/\/doi.org\/10.1016\/j.ophtha.2011.09.008","journal-title":"Ophthalmology"},{"key":"2577_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121943","author":"E Aric\u00f2","year":"2019","unstructured":"Aric\u00f2 E, Castiello L, Capone I et al (2019) Type i interferons and cancer: An evolving story demanding novel clinical applications. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11121943","journal-title":"Cancers (Basel)"},{"key":"2577_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMoa013376","volume":"347","author":"O Hermine","year":"2002","unstructured":"Hermine O, Lefr\u00e8re F, Bronowicki J-P et al (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347:89\u201394. https:\/\/doi.org\/10.1056\/NEJMoa013376","journal-title":"N Engl J Med"},{"key":"2577_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bjh.15760","volume":"186","author":"J Cannata-Ortiz","year":"2019","unstructured":"Cannata-Ortiz J, Nicol\u00e1s C, Garc\u00eda-Noblejas A et al (2019) Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI \u2265 2 follicular lymphoma. Final results of the LNH-PRO-05 study. Br J Haematol 186:168\u2013170. https:\/\/doi.org\/10.1111\/bjh.15760","journal-title":"Br J Haematol"},{"key":"2577_CR44","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.1998.16.7.2339","volume":"16","author":"BF Cole","year":"1998","unstructured":"Cole BF, Solal-C\u00e9ligny P, Gelber RD et al (1998) Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 16:2339\u20132344. https:\/\/doi.org\/10.1200\/JCO.1998.16.7.2339","journal-title":"J Clin Oncol"},{"key":"2577_CR45","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1200\/JCO.1998.16.4.1538","volume":"16","author":"R Arranz","year":"1998","unstructured":"Arranz R, Garc\u00eda-Alfonso P, Sobrino P et al (1998) Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin\u2019s lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol 16:1538\u20131546. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1538","journal-title":"J Clin Oncol"},{"key":"2577_CR46","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","volume":"23","author":"AZS Rohatiner","year":"2005","unstructured":"Rohatiner AZS, Gregory WM, Peterson B et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215\u20132223. https:\/\/doi.org\/10.1200\/JCO.2005.06.146","journal-title":"J Clin Oncol"},{"key":"2577_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fimmu.2013.00483","volume":"4","author":"G Schiavoni","year":"2013","unstructured":"Schiavoni G, Mattei F, Gabriele L (2013) Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response. Front Immunol 4:483. https:\/\/doi.org\/10.3389\/fimmu.2013.00483","journal-title":"Front Immunol"},{"key":"2577_CR48","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/toxins6061696","volume":"6","author":"S Gessani","year":"2014","unstructured":"Gessani S, Conti L, Del Corn\u00f2 M, Belardelli F (2014) Type I interferons as regulators of human antigen presenting cell functions. Toxins (Basel) 6:1696\u20131723. https:\/\/doi.org\/10.3390\/toxins6061696","journal-title":"Toxins (Basel)"},{"key":"2577_CR49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/jid.2010.256","volume":"131","author":"W Vermi","year":"2011","unstructured":"Vermi W, Fisogni S, Salogni L et al (2011) Spontaneous regression of highly immunogenic Molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J Invest Dermatol 131:426\u2013434. https:\/\/doi.org\/10.1038\/jid.2010.256","journal-title":"J Invest Dermatol"},{"key":"2577_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/CJI.0000000000000266","volume":"42","author":"A Hirn Lopez","year":"2019","unstructured":"Hirn Lopez A, Deen D, Fischer Z et al (2019) Role of interferon (IFN)\u03b1 in \u201cCocktails\u201d for the generation of (Leukemia-derived) dendritic cells (DCleu) from blasts in blood from patients (pts) with acute myeloid leukemia (AML) and the Induction of antileukemic reactions. J Immunother 42:143\u2013161. https:\/\/doi.org\/10.1097\/CJI.0000000000000266","journal-title":"J Immunother"},{"key":"2577_CR51","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1182\/blood-2003-03-0981","volume":"103","author":"L Gabriele","year":"2004","unstructured":"Gabriele L, Borghi P, Rozera C et al (2004) IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 103:980\u2013987. https:\/\/doi.org\/10.1182\/blood-2003-03-0981","journal-title":"Blood"},{"key":"2577_CR52","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00262-019-02406-9","volume":"68","author":"JK Bialek-Waldmann","year":"2019","unstructured":"Bialek-Waldmann JK, Heuser M, Ganser A, Stripecke R (2019) Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-\u03b12 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. Cancer Immunol Immunother 68:1891\u20131899. https:\/\/doi.org\/10.1007\/s00262-019-02406-9","journal-title":"Cancer Immunol Immunother"},{"key":"2577_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1445-5994.2001.00013.x","volume":"31","author":"A Grigg","year":"2001","unstructured":"Grigg A, Kannan K, Schwarer AP et al (2001) Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation. Intern Med J 31:15\u201322. https:\/\/doi.org\/10.1046\/j.1445-5994.2001.00013.x","journal-title":"Intern Med J"},{"key":"2577_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cytogfr.2014.10.002","volume":"26","author":"P Rizza","year":"2015","unstructured":"Rizza P, Moretti F, Capone I, Belardelli F (2015) Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev 26:195\u2013201. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.10.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"2577_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","volume":"14","author":"A Le Bon","year":"2001","unstructured":"Le Bon A, Schiavoni G, D\u2019Agostino G et al (2001) Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461\u2013470. https:\/\/doi.org\/10.1016\/S1074-7613(01)00126-1","journal-title":"Immunity"},{"key":"2577_CR56","doi-asserted-by":"publisher","first-page":"e1356964","DOI":"10.1080\/2162402X.2017.1356964","volume":"6","author":"B Montico","year":"2017","unstructured":"Montico B, Lapenta C, Ravo M et al (2017) Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. Oncoimmunology 6:e1356964. https:\/\/doi.org\/10.1080\/2162402X.2017.1356964","journal-title":"Oncoimmunology"},{"key":"2577_CR57","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.exphem.2006.12.004","volume":"35","author":"E Brillard","year":"2007","unstructured":"Brillard E, Pallandre J-R, Chalmers D et al (2007) Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes. Exp Hematol 35:416\u2013425. https:\/\/doi.org\/10.1016\/j.exphem.2006.12.004","journal-title":"Exp Hematol"},{"key":"2577_CR58","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/cmi.2013.2","volume":"10","author":"I Pedroza-Pacheco","year":"2013","unstructured":"Pedroza-Pacheco I, Madrigal A, Saudemont A (2013) Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol 10:222\u2013229. https:\/\/doi.org\/10.1038\/cmi.2013.2","journal-title":"Cell Mol Immunol"},{"key":"2577_CR59","doi-asserted-by":"publisher","first-page":"e22763","DOI":"10.1371\/journal.pone.0022763","volume":"6","author":"N Bacher","year":"2011","unstructured":"Bacher N, Graulich E, Jonuleit H et al (2011) Interferon-\u03b1 abrogates tolerance induction by human tolerogenic dendritic cells. PLoS ONE 6:e22763. https:\/\/doi.org\/10.1371\/journal.pone.0022763","journal-title":"PLoS ONE"},{"key":"2577_CR60","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CJI.0b013e318167b023","volume":"31","author":"M Gigante","year":"2008","unstructured":"Gigante M, Mandic M, Wesa AK et al (2008) Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 31:254\u2013262. https:\/\/doi.org\/10.1097\/CJI.0b013e318167b023","journal-title":"J Immunother"},{"key":"2577_CR61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1055\/s-2007-1022565","volume":"40","author":"C Papewalis","year":"2008","unstructured":"Papewalis C, Wuttke M, Jacobs B et al (2008) Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 40:108\u2013116. https:\/\/doi.org\/10.1055\/s-2007-1022565","journal-title":"Horm Metab Res"},{"key":"2577_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02411-y","author":"C Lapenta","year":"2019","unstructured":"Lapenta C, Donati S, Spadaro F et al (2019) Lenalidomide improves the therapeutic effect of an interferon-\u03b1-dendritic cell-based lymphoma vaccine. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-019-02411-y","journal-title":"Cancer Immunol Immunother"},{"key":"2577_CR63","doi-asserted-by":"publisher","first-page":"e1232220","DOI":"10.1080\/2162402X.2016.1232220","volume":"5","author":"J Weng","year":"2016","unstructured":"Weng J, Baio FE, Moriarty KE et al (2016) Targeting B-cell malignancies through human B-cell receptor specific CD4 + T cells. Oncoimmunology 5:e1232220. https:\/\/doi.org\/10.1080\/2162402X.2016.1232220","journal-title":"Oncoimmunology"},{"key":"2577_CR64","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","volume":"133","author":"MS Khodadoust","year":"2019","unstructured":"Khodadoust MS, Olsson N, Chen B et al (2019) B-cell lymphomas present immunoglobulin neoantigens. Blood 133:878\u2013881. https:\/\/doi.org\/10.1182\/blood-2018-06-845156","journal-title":"Blood"},{"key":"2577_CR65","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","volume":"19","author":"CL-L Chiang","year":"2013","unstructured":"Chiang CL-L, Kandalaft LE, Tanyi J et al (2013) A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 19:4801\u20134815. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1185","journal-title":"Clin Cancer Res"},{"key":"2577_CR66","doi-asserted-by":"publisher","first-page":"19220","DOI":"10.1002\/jcb.29241","volume":"120","author":"J Liu","year":"2019","unstructured":"Liu J, Wang X (2019) Focus on exosomes\u2014From pathogenic mechanisms to the potential clinical application value in lymphoma. J Cell Biochem 120:19220\u201319228. https:\/\/doi.org\/10.1002\/jcb.29241","journal-title":"J Cell Biochem"},{"key":"2577_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.exphem.2016.11.004","volume":"46","author":"M-C Vo","year":"2017","unstructured":"Vo M-C, Anh-NguyenThi T, Lee H-J et al (2017) Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. Exp Hematol 46:48\u201355. https:\/\/doi.org\/10.1016\/j.exphem.2016.11.004","journal-title":"Exp Hematol"},{"key":"2577_CR68","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/leu.2013.177","volume":"28","author":"I Sakamaki","year":"2014","unstructured":"Sakamaki I, Kwak LW, Cha SC et al (2014) Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 28:329\u2013337. https:\/\/doi.org\/10.1038\/leu.2013.177","journal-title":"Leukemia"},{"key":"2577_CR69","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","volume":"38","author":"T-N Nguyen-Pham","year":"2015","unstructured":"Nguyen-Pham T-N, Jung S-H, Vo M-C et al (2015) Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma. J Immunother 38:330\u2013339. https:\/\/doi.org\/10.1097\/CJI.0000000000000097","journal-title":"J Immunother"},{"key":"2577_CR70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","volume":"131","author":"C Chester","year":"2018","unstructured":"Chester C, Sanmamed MF, Wang J, Melero I (2018) Immunotherapy targeting 4\u20131BB: mechanistic rationale, clinical results, and future strategies. Blood 131:49\u201357. https:\/\/doi.org\/10.1182\/blood-2017-06-741041","journal-title":"Blood"},{"key":"2577_CR71","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"key":"2577_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","volume":"15","author":"JR Westin","year":"2014","unstructured":"Westin JR, Chu F, Zhang M et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15:69\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(13)70551-5","journal-title":"Lancet Oncol"},{"key":"2577_CR73","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH et al (2018) Successful Anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity 49:1148\u20131161.e7. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.024","journal-title":"Immunity"},{"key":"2577_CR74","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","volume":"26","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Nowakowski GS, Habermann TM et al (2015) A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol Off J Eur Soc Med Oncol 26:1667\u20131677. https:\/\/doi.org\/10.1093\/annonc\/mdv102","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2577_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/ejh.13065","volume":"101","author":"M Palma","year":"2018","unstructured":"Palma M, Hansson L, Mulder TA et al (2018) Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. Eur J Haematol 101:68\u201377. https:\/\/doi.org\/10.1111\/ejh.13065","journal-title":"Eur J Haematol"},{"key":"2577_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/2162402X.2014.990773","volume":"4","author":"MC Cox","year":"2015","unstructured":"Cox MC, Battella S, La Scaleia R et al (2015) Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology 4:1\u201312. https:\/\/doi.org\/10.4161\/2162402X.2014.990773","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02577-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:23:38Z","timestamp":1619047418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02577-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2577"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02577-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"16 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Stefano M. Santini received research funding from Celgene. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This is a review and not an original paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Not applicable. This is a review and not an original paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}